Pawel Potocki - Jagiellonian University

基本信息

Career Trajectory

Bio

Currently working on: Colorectal cancer EGFR-targeted therapy - real-life study; Metronomic chemotherapy in breast, gastrointestinal, ovarian cancers - early clinical data. KRAS & BRAF mutations in colorectal cancers BRAFmut and MSI interplay in colorectal cancer. FOLFIRINOX regimen deescalation in pancreatic cancer

Research Interests

Papers共 42 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Neoadjuvant Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy for Muscle-Invasive Urothelial Cancer: Large, Single-Center Analysis of Consecutive Patients’ Data

Lukasz Kwinta,Kamil Konopka,Krzysztof Okon,Mateusz Lobacz,Piotr Chlosta,Przemyslaw Dudek,Anna Buda-Nowak,Pawel Potocki,Piotr J. Wysocki

CANCERS（2025）

Cited0Views0WOSBibtex

Michal Seweryn,Tomasz Banas,Joanna Augustynska, Agnieszka Leszczynska,Pawel M. Potocki

ONCOLOGY IN CLINICAL PRACTICE（2024）

Cited0Views0Bibtex

Dendritic Cell Immunotherapy and Topotecan-Based Metronomic Chemotherapy in Ovarian Cancer — a Case Study and Literature Review

Patrycja Mrowczyk, Maria Rozploch-Sapa,Pawel M. Potocki

ONCOLOGY IN CLINICAL PRACTICE（2024）

Cited0Views0Bibtex

Do Solitary Pancreatic Metastases of Renal-Cell Carcinoma Indicate an Indolent Disease with a Strong Indication for Aggressive Local Treatment? A Case Report with Literature Review

Jolanta Dobrzanska,Pawel Potocki,Piotr J. Wysocki

ONCOLOGY IN CLINICAL PRACTICEno. 1 (2024): 68-70

Cited1Views0Bibtex

Durable Complete Remission of Metastatic Gastric Cancer Following Platinum-Based Chemotherapy: A Case Report

Weronika Pilch, Wiktoria Wojturska,Pawel M Potocki

Cureusno. 12 (2024): e76378-e76378

Cited0Views0WOSBibtex

Long-term Survival and Remarkably Durable Treatment Response in a Case of Inoperable Fibrolamellar Carcinoma of the Liver — a Comprehensive Analysis of an 8-Year Chemotherapeutic Journey

Bartosz T. Wojewoda,Magdalena Ulatowska-Bialas,Pawel M. Potocki

Oncology in Clinical Practice (2024)

Cited0Views0Bibtex

Low-grade Serous Ovarian Cancer with BRAFV600E Mutation Treated with Metronomic Chemotherapy - a Case Report and Literature Review

Maria Rozploch-Sapa, Patrycja Mrowczyk,Lukasz Kwinta,Mateusz Lobacz,Pawel M. Potocki

ONCOLOGY IN CLINICAL PRACTICE（2024）

Cited0Views0Bibtex

Metronomic Chemo-Endocrine Therapy (fulvec) As a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer—A Retrospective Analysis of Consecutive Patients Data

Anna Buda-Nowak,Lukasz Kwinta,Pawel Potocki,Anna Michalowska-Kaczmarczyk,Agnieszka Slowik,Kamil Konopka,Joanna Streb,Maciej Koniewski,Piotr J. J. Wysocki

Journal of Clinical Medicine (2023)

Cited9Views0WOSBibtex

Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer-A Nation-Wide Study

Pawel M. Potocki,Piotr Wojcik,Lukasz Chmura,Bartlomiej Goc,Marcin Fedewicz,Zofia Bielanska,Jakub Swadzba,Kamil Konopka,Lukasz Kwinta,Piotr J. Wysocki

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES（2023）

Cited4Views0WOSBibtex

Metronomic chemo-endocrine treatment (FulVEC) for patients with advanced hormone-refractory ER plus breast cancer

Anna Buda-Nowak,Lukasz Kwinta,Pawel Potocki,Joanna Streb,Piotr Wysocki

CANCER RESEARCHno. 5 (2023)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn